JP2019534858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534858A5 JP2019534858A5 JP2019513444A JP2019513444A JP2019534858A5 JP 2019534858 A5 JP2019534858 A5 JP 2019534858A5 JP 2019513444 A JP2019513444 A JP 2019513444A JP 2019513444 A JP2019513444 A JP 2019513444A JP 2019534858 A5 JP2019534858 A5 JP 2019534858A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ligand according
- peptide
- ligand
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims description 88
- 206010028980 Neoplasm Diseases 0.000 claims description 62
- 201000011510 cancer Diseases 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 235000001014 amino acid Nutrition 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims description 12
- 102100039676 Frizzled-7 Human genes 0.000 claims description 12
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims description 12
- 101000643895 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 6 Proteins 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 102100021015 Ubiquitin carboxyl-terminal hydrolase 6 Human genes 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 230000002018 overexpression Effects 0.000 claims description 12
- 201000002528 pancreatic cancer Diseases 0.000 claims description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 108050007985 Frizzled-7 Proteins 0.000 claims description 8
- 102100028461 Frizzled-9 Human genes 0.000 claims description 8
- 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 102100021259 Frizzled-1 Human genes 0.000 claims description 4
- 102100021261 Frizzled-10 Human genes 0.000 claims description 4
- 102100021265 Frizzled-2 Human genes 0.000 claims description 4
- 102100039820 Frizzled-4 Human genes 0.000 claims description 4
- 102100039818 Frizzled-5 Human genes 0.000 claims description 4
- 102100039799 Frizzled-6 Human genes 0.000 claims description 4
- 102100028466 Frizzled-8 Human genes 0.000 claims description 4
- 101000819438 Homo sapiens Frizzled-1 Proteins 0.000 claims description 4
- 101000819451 Homo sapiens Frizzled-10 Proteins 0.000 claims description 4
- 101000819477 Homo sapiens Frizzled-2 Proteins 0.000 claims description 4
- 101000819458 Homo sapiens Frizzled-3 Proteins 0.000 claims description 4
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 claims description 4
- 101000885585 Homo sapiens Frizzled-5 Proteins 0.000 claims description 4
- 101000885673 Homo sapiens Frizzled-6 Proteins 0.000 claims description 4
- 101001061408 Homo sapiens Frizzled-8 Proteins 0.000 claims description 4
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 4
- 125000005473 octanoic acid group Chemical group 0.000 claims description 4
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical group CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical group C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 2
- SLVKVPLSFLVIOD-UHFFFAOYSA-N 2-amino-3-decoxypropanoic acid Chemical compound NC(C(=O)O)COCCCCCCCCCC SLVKVPLSFLVIOD-UHFFFAOYSA-N 0.000 claims description 2
- JINGUCXQUOKWKH-UHFFFAOYSA-N 2-aminodecanoic acid Chemical compound CCCCCCCCC(N)C(O)=O JINGUCXQUOKWKH-UHFFFAOYSA-N 0.000 claims description 2
- OLUWXTFAPJJWPL-YFKPBYRVSA-N 6-hydroxy-l-norleucine Chemical compound OC(=O)[C@@H](N)CCCCO OLUWXTFAPJJWPL-YFKPBYRVSA-N 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 2
- FMUMEWVNYMUECA-UHFFFAOYSA-N L-homoleucine Natural products CC(C)CCC(N)C(O)=O FMUMEWVNYMUECA-UHFFFAOYSA-N 0.000 claims description 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical group OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 210000004966 intestinal stem cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385848P | 2016-09-09 | 2016-09-09 | |
| US62/385,848 | 2016-09-09 | ||
| US201662419331P | 2016-11-08 | 2016-11-08 | |
| US62/419,331 | 2016-11-08 | ||
| PCT/US2017/050841 WO2018049275A1 (en) | 2016-09-09 | 2017-09-08 | Selective peptide inhibitors of frizzled |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534858A JP2019534858A (ja) | 2019-12-05 |
| JP2019534858A5 true JP2019534858A5 (OSRAM) | 2020-10-22 |
Family
ID=60022161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513444A Pending JP2019534858A (ja) | 2016-09-09 | 2017-09-08 | Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190359653A1 (OSRAM) |
| EP (1) | EP3509616A1 (OSRAM) |
| JP (1) | JP2019534858A (OSRAM) |
| CN (1) | CN110198729A (OSRAM) |
| WO (1) | WO2018049275A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020102664A1 (en) * | 2018-11-16 | 2020-05-22 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Biomarkers and treatment of neuronal injury and neurodegeneration |
| CN112210011A (zh) * | 2019-11-06 | 2021-01-12 | 上海健康医学院 | 一种靶向Frizzled7人源化抗体及其制备方法与应用 |
| TW202535907A (zh) * | 2023-11-10 | 2025-09-16 | 日商肽夢想股份有限公司 | 胜肽、胜肽複合體、醫藥組成物、細胞培養用組成物、以及用於醫療用、診斷用或是研究用之組成物 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE3546807C2 (OSRAM) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| EP0760012A4 (en) | 1994-06-10 | 1997-07-02 | Symbiotech Inc | METHODS FOR DETECTING COMPOUNDS BY MEANS OF GENETICALLY MODIFIED LAMBDA BACTERIOPHAGE |
| US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| JPH11507246A (ja) | 1996-03-20 | 1999-06-29 | ダイアックス コープ． | 巨大分子用アフィニティ・リガンドの設計 |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| KR20000016414A (ko) | 1996-06-06 | 2000-03-25 | 와이즈먼 앤드루 | Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법 |
| ATE279203T1 (de) | 1996-06-10 | 2004-10-15 | Scripps Research Inst | Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten |
| US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| EP0929361A4 (en) | 1996-10-04 | 2000-07-19 | Whatman Inc | DEVICE AND METHOD FOR SIMULTANEOUS MULTIPLE SYNTHESIS |
| JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
| WO1998020036A1 (en) | 1996-11-06 | 1998-05-14 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
| IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| CN1204147C (zh) | 1998-02-25 | 2005-06-01 | 利思进药品公司 | 提高以抗体为基础的融合蛋白的循环半衰期的方法 |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| WO2006036175A2 (en) * | 2004-09-21 | 2006-04-06 | Rhode Island Hospital, A Lifespan-Partner | Wnt proteins and detection and treatment of cancer |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| TWI506037B (zh) * | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| WO2011123785A2 (en) * | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| CA2921398C (en) * | 2013-08-14 | 2021-12-14 | The Governing Council Of The University Of Toronto | Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors |
| EP2975047A1 (en) * | 2014-07-18 | 2016-01-20 | Université de Lausanne | Wnt7a polypeptides and their use |
-
2017
- 2017-09-08 JP JP2019513444A patent/JP2019534858A/ja active Pending
- 2017-09-08 WO PCT/US2017/050841 patent/WO2018049275A1/en not_active Ceased
- 2017-09-08 CN CN201780065292.9A patent/CN110198729A/zh active Pending
- 2017-09-08 EP EP17780550.4A patent/EP3509616A1/en not_active Withdrawn
-
2019
- 2019-03-04 US US16/292,099 patent/US20190359653A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019196365A5 (OSRAM) | ||
| ES2383824T3 (es) | Inhibidores peptídicos con permeabilidad celular de la ruta de transducción de la señal JNK | |
| AU2019253863A1 (en) | Cysteine engineered fibronectin type III domain binding molecules | |
| EP1911458B9 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| JP2016052315A5 (OSRAM) | ||
| JP2012509659A5 (OSRAM) | ||
| JP2016187356A5 (OSRAM) | ||
| US20240294590A1 (en) | Nucleic acid encoding genetically engineered growth factor variants | |
| JP2022514687A5 (OSRAM) | ||
| JP2019535763A5 (OSRAM) | ||
| JP2010053136A5 (OSRAM) | ||
| JP2010519176A5 (OSRAM) | ||
| JP2017514812A5 (OSRAM) | ||
| JP2017501130A5 (OSRAM) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение | |
| JP2017529097A5 (OSRAM) | ||
| JP2016506911A (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2010536714A5 (OSRAM) | ||
| BR112019021056B1 (pt) | Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular | |
| JP2022502347A (ja) | 細胞透過性ペプチド | |
| CN108699110A (zh) | 整合素结合肽及其用途 | |
| CN116134138B (zh) | 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途 | |
| JP2018537117A5 (OSRAM) | ||
| JP2011523405A5 (OSRAM) | ||
| JP2010537623A5 (OSRAM) |